Dan O'Day, Gilead CEO (Jim Watson/AFP via Getty Images)

Fail­ing to con­firm clin­i­cal ben­e­fit, Gilead pulls 2 ac­cel­er­at­ed ap­proval in­di­ca­tions for can­cer drug

Gilead re­cent­ly de­cid­ed to pull two in­di­ca­tions for its can­cer drug Zy­delig — in re­lapsed fol­lic­u­lar B-cell non-Hodgkin lym­phoma (FL) and re­lapsed small lym­pho­cyt­ic leukemia …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.